Literature DB >> 3805326

The pharmacological treatment of delusional depression: Part II.

D G Spiker, J M Perel, I Hanin, R S Dealy, S J Griffin, P H Soloff, J C Weiss.   

Abstract

This study investigated the pharmacological treatment of delusional depressives by assigning patients on a random double-blind basis to amitriptyline (AT) alone, perphenazine (PER) alone, or AT + PER. As reported in an earlier paper, the combination of AT + PER was the superior treatment with a response rate of 78% compared with 41% for AT alone and 19% for PER alone. This difference is both clinically and statistically significant (p less than 0.01). In this second article, the authors report that the patients on AT + PER had higher plasma levels of AT and its pharmacologically active metabolite nortriptyline (NT) than the patients on AT alone. Although the response rate had a direct relationship to AT + NT plasma levels, an analysis of variance showed that the group of patients treated with AT + PER still had a significantly higher response rate, even after controlling for the plasma levels of AT + NT (p less than 0.05). There was also a correlation between PER plasma levels and clinical response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3805326

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 3.  Pharmacological treatment for psychotic depression.

Authors:  Jacolien Kruizinga; Edith Liemburg; Huibert Burger; Andrea Cipriani; John Geddes; Lindsay Robertson; Beatrix Vogelaar; Willem A Nolen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.